Discontinuing Low-Dose Aspirin Ups Cardiovascular Risk

Share this content:
Discontinuing Low-Dose Aspirin Ups Cardiovascular Risk
Discontinuing Low-Dose Aspirin Ups Cardiovascular Risk

MONDAY, Sept. 25, 2017 (HealthDay News) -- There is more than a 30 percent increased risk of cardiovascular events following discontinuation of low-dose aspirin in long-term users, according to a study published in the Sept 26 issue of Circulation.

Johan Sundström, M.D., Ph.D., from Uppsala University in Sweden, and colleagues used the Swedish prescription register (2005 through 2009) to identify 601,527 users of low-dose aspirin for primary or secondary prevention who were >40 years of age, free from previous cancer, and had ≥80 percent adherence during the first observed year of treatment. The Swedish inpatient and cause-of-death registers were used to identify cardiovascular events.

The researchers found that over a median of 3.0 years of follow-up, there were 62,690 cardiovascular events. There was a higher rate of cardiovascular events among patients who discontinued aspirin versus those who continued (multivariable-adjusted hazard ratio, 1.37). This rate translates to an additional cardiovascular event observed per year in one of every 74 patients who discontinue aspirin. The elevated risk appeared shortly after discontinuation and did not appear to diminish over time.

"Adherence to low-dose aspirin treatment in the absence of major surgery or bleeding is likely an important treatment goal," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »